Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer (original) (raw)

Journal Article

,

Department of Internal Medicine, Osaka Prefectural Habikino Hospital

Habikino City, Osaka, Japan

Search for other works by this author on:

,

Department of Internal Medicine, National Kinki Central Hospital

Sakai City, Osaka

Search for other works by this author on:

,

Department of Internal Medicine, National Cancer Center Hospital

Chuou-ku, Tokyo, Japan

*Correspondence to: Nagahiro Saijo, M.D., Pharmacology Division and Medical Oncology, National Cancer Center Research Institute, I - 1 Tsukiji 5-chome, Chuo-ku, Tokyo 104, Japan.

Search for other works by this author on:

,

Department of Internal Medicine, National Matsudo Hospital

Matsudo City, Chiba, Japan

Search for other works by this author on:

,

Department of Respiratory Disease, the Center for Adult Disease

Osaka, Higashinari-ku, Osaka

Search for other works by this author on:

,

Department of Internal Medicine, National Cancer Center Hospital

Chuou-ku, Tokyo, Japan

Search for other works by this author on:

,

Department of Internal Medicine, National Cancer Center Hospital

Chuou-ku, Tokyo, Japan

Search for other works by this author on:

Department of Thoracic Surgey, National Cencer Center Hospital

Chuou-ku, Tokyo, Japan

Search for other works by this author on:

Received:

22 January 1991

Revision received:

26 March 1991

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Masahiro Fukuoka, Kiyoyuki Furuse, Nagahiro Saijo, Yutaka Nishiwaki, Harumichi Ikegami, Tomohide Tamura, Masanori Shimoyama, Keiichi Suemasu, Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer, JNCI: Journal of the National Cancer Institute, Volume 83, Issue 12, 19 June 1991, Pages 855–861, https://doi.org/10.1093/jnci/83.12.855
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

Between April 1985 and May 1988, we conducted a randomized study comparing two standard chemotherapy regimens with the same regimens given on an alternating basis in patients with small-cell lung cancer. The patients were randomly assigned to receive cyclophosphamide at a dose of 800 mg/m 2 intravenously (IV) on day 1, doxorubicin at 50 mg/m 2 IV on day 1, and vincristine at 1.4 mg/m 2 IV on day 1 (CAV); cisplatin at 80 mg/m 2 IV on day 1 and etoposide at 100 mg/m 2 IV on days 1, 3, and 5 (PE); or CAV alternating with PE (CAV/PE). Each regimen was repeated every 3–4 weeks. Three hundred patients were entered in the study, and 288 of them were eligible for analysis (97 for CAV, 97 for PE, and 94 for CAV/PE). The response rates for PE (78%) and CAV/PE (76%) were significantly higher than the rate for CAV (55%), while the complete response rates were similar (14%, 16%, and 15%, respectively). Nine (23%) of 39 patients who failed to respond to the initial CAV regimen responded to PE when they were crossed over. In contrast, only one (8%) of 13 patients responded to CAV after failing to respond to the PE regimen, suggesting that these two regimens were partially non-cross-resistant. The response duration on CAV/PE was significantly longer than that with CAV ( P = .004). The survival time with CAV/PE (11.8 months) was superior to that with CAV (9.9 months) ( P = .027) or that with PE (9.9 months) ( P equals; .056). In patients with limited disease, the survival in the alternating arm was significantly superior to the survival in the CAV arm ( P = .014) or the survival in the PE arm ( P =.023). The toxic effects were acceptable in all three chemotherapy regimens. These results favor the alternating chemotherapy over either standard chemotherapy, such as CAV and PE, although the differences are not dramatic. [J Natl Cancer Inst 83:855–861, 1991]

This content is only available as a PDF.

© Oxford University Press

Topic:

• doxorubicin
• cancer
• small cell carcinoma of lung
• chemotherapy regimen
• cisplatin
• cyclophosphamide
• etoposide
• vincristine
• arm
• toxic effect
• frequency of responses
• pe regimen
• complete remission

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer - 24 Hours access

EUR €38.00

GBP £33.00

USD $41.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 299

37 Pageviews

262 PDF Downloads

Since 1/1/2017

Citations

374 Web of Science

×

Email alerts

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic